Dongsun medicine won the first imitation 28.5 billion oral sugar-lowering drug market shuffle 57 new DPP4 products on the way.

East Sunshine medicine took the first imitation, Ligretin sales growth of more than 100% July 13, NMPA official website shows that the East Sunshine drug according to imitation 4 categories of declared Ligretin tablets approved and treated as the same review, approved the number of the national drug quasi-word H20203294, successfully won the Ligret tablet domestic first imitationDongsun drug in the field of diabetes treatment layout of a complete product line, in June this year, the company was approved the first biological drug - recombinant human insulin injection, previously approved of the glutine capsule, followed by the siglitin, Agretin, Ronggrenet, liraglutide and three or four generations of insulin and other products listed, diabetes pipeline into the harvest periodLiglitin is a powerful, highly selective dipeptide-4 (DPP-4) inhibitor class oral anti-sugar drug, used in combination with metformin and sulfonate drugs, in conjunction with dietary control and exercise, to improve blood glucose control in patients with type 2 diabetesLiglitin is currently the lowest level of renal excretion of DPP-4 inhibitors, is the first approved DPP-4 inhibitor without reducing doses based on renal functionThe Liglitin tablets were developed by Bollinger Ingham and were approved by the FDA in 2011 and imported by the State Drug Administration in 2013According to the results, the global sales of Liglitin and its complex in 2019 were EUR 1,559 millionAccording to Minnet.com, sales of Ligretin tablets at the end of China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) in 2019 were 246 million yuanIt is worth mentioning that since the domestic listing of Ligretin tablets in the domestic market sales, the annual growth rate of more than 100%China's public medical institutions terminal Ligretin film sales (units: 10,000 yuan) collection price, DPP4 rise! 28.5 billion market shuffle There are five approved DPP-4 inhibitors in China, namely Siglitin, Sagretin, Viglitin, Liglitin and AglitinOverall, five DPP-4 inhibitors have been approved for import for many years, and the first imitation sits on the market in 2019 and 2020Domestic first DPP4 inhibitor generic sagretin tablets, the product developed after 7 years, followed by Hausson Pharmaceuticals won the first imitation of The vegrestine tablets, Abao Pharmaceuticals took the first imitation of benzoic acid agretin tablets, Zhengda Tianqing Pharmaceutical Group took the first imitation of the phosphoric acid sigretin tablets, East Sunshine medicine took the first imitation of The Ligretin tablets, 5 dpp-4 inhibitors the first imitation battle endedAccording to data from the domestic marketed DPP4 inhibitor Minnet Net, sales of oral sugar-lowering drugs in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) exceeded 28.5 billion yuan in 2019, up 15.01 percent year-on-yearThe top3 varieties of oral sugar-lowering drugs were acapo sugar, metformin and greme, with sales growth rates of 13.81 percent, 19.22 percent and 12.34 percent, respectively, in 2019China's public medical institutions terminal oral sugar-lowering drugs sales (units: 10,000 yuan) compared to other oral anti-sugar drugs, DPP-4 inhibitors because of the rapid oral absorption, not easy to induce hypoglycemia and weight gain and other advantages, has been welcomed by the marketMinnet data show that in 2019 China's public medical institutions terminal 5 DPP-4 inhibitor sales performance is not bad! Liglitin tablets led the sales growth rate of 104.17%, the annual sales of sigredine phosphate tablets close to 1 billion yuan, benzoic acid aglitinsin tablet sales will soon pass the billion yuan markMarket DPP4 inhibitor sales situation Oral sugar-lowering drugs are an important category in the field of chronic disease treatment, diabetic patients need to take drugs for life, so sugar-lowering drugs have become one of the key targets of national and provincial band procurementThe second batch of collected varieties included two best-selling oral anti-sugar drugs, Acapo sugar and Gremeyre, while the drug metformin and THE DPP-4 inhibitor Virgretin were the third batch of proposed collection varieties With the main varieties of oral sugar-lowering drugs set large price reduction, DPP-4 inhibitor generic drugs have been approved to grab the food market, oral sugar-lowering drug market is likely to usher in a shuffle 57 new products on the road, Collum sprint first imitation DPP-4 inhibitorised is a new target for the treatment of type 2 diabetes, in the oral sugar-lowering drug market has a pivotal position, a number of domestic pharmaceutical companies competing for imitation According to The Inner Net data, there are still 57 applications for imitation of THE DPP-4 inhibitors in the review In the review of the DPP-4 inhibitor generics listing application phosphoric acid sigreitin tablets in the review of the imitation application number has 18, involving stone drug Ouyi, Dongsun medicine, Nanjing Zhengda Tianqing, Yangzijiang Pharmaceutical Group, Koren Pharmaceuticals, Tonghua Dongbao and other 9 enterprises Benzoic acid agrestine tablets in the review of the imitation application number has 16, involving stone medicine European-, East Sunshine medicine, Thousand Jinxiangjiang, Yabao Pharmaceuticals and other 10 enterprises Vegretin tablets have been approved for production of 4 pharmaceutical companies, in the review of the imitation application acceptance number of 10, involving Yangzijiang Pharmaceutical Group, China Resources Seko, Yuxin Pharmaceuticals and other 10 enterprises There are fewer companies in the layout of sagretin tablets and Liglitin tablets There are five generic applicationacceptance numbers in the review of Sagretin tablets, involving enterprises such as Qilu Pharmaceuticals, Haussen Pharmaceuticals, zhengda Tianqing Pharmaceutical Group Liglitin tablet imitation application in the review of the enterprise only stone drug Oyi, Yangzijiang Pharmaceutical Group The application for listing of hydrobromic acid for Gretin tablets in the trial enterpriseS It is worth mentioning that hydrobromic acid for Gretin tablets in China has not been approved for original research and imitation The original research manufacturer Tianbian Mitsubishi Pharmaceuticals submitted the application for the import of hydrogen brominated acid for Gretin tablets on September 28, 2019 was accepted by CDE, Collum Pharmaceuticals exclusive application for imitation, the high probability of taking the hydrogen bromine for Gretin tablets first imitation Under the active layout of a number of domestic enterprises, more and more generic drugs will be approved for listing, DPP-4 inhibitor market will be further expanded Source: Minnet database, company announcement Note: statistics as of July 16, if there are omissions, welcome to point! Original title: East Sunshine medicine took the first imitation, 28.5 billion oral sugar-lowering drug market shuffle! 57 DPP4 new products on the way, Curran sprinted to the first imitation.